Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
N/A
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07640867Phase 1Completed

RCI001 Eye Drops 0.25% in Healthy Adult Male Participants

Role: lead

NCT07625124Phase 2Not Yet Recruiting

A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease

Role: lead

NCT04986501Not ApplicableCompleted

Clinical Evaluation of MucoPEG™ for Xerostomia

Role: collaborator

All 3 trials loaded